ArticleJournal of diabetes research2025
A Qualitative Analysis of Provider-Level Barriers to Prescribing Diabetes Technology.
Article in Journal of diabetes research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Technology in Diabetes: A Year in Review.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026Review
- A Flexible Wearable Glucose Sensor for Noninvasive Diabetes Screening: Functional Equivalence and Model Interpretability.Biosensors · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Patient utilization of diabetes technology differs based on sociodemographic and other factors. Underserved patients have reported that providers decline to prescribe continuous glucose monitors (CGMs) and insulin pumps. This qualitative study elucidated provider perspectives regarding facilitators and barriers to the prescription and patient use of diabetes technology. Methods: Sixteen diabetes care providers (75.0% MD, 18.8% APRN, 6.3% PharmD, and 50.0% adult endocrinology) at academic health centers, a Veterans Affairs Medical Center, and a safety net hospital in the southeastern United States were surveyed and interviewed from January to May 2024. Survey data were analyzed using descriptive statistics; a thematic analysis was used for interview transcripts with an adapted version of the social-ecological model (SEM) as the coding framework. Results: On the survey, providers estimated that 80% (IQR 58.0%-86.0%) of their patients who met American Diabetes Association criteria for CGMs and 50% (IQR 48.0%-63.0%) for insulin pumps regularly used them. System factors (e.g., lack of insurance, high device costs, and insurance bureaucracy) were perceived by providers (62.5%-93.8%) as patients' top barriers to use. Across the interviews ( Conclusions: These findings indicate the need for multilevel solutions to improve the prescription and use of diabetes technology. Future research and clinical practice should aim to enhance EHR functionality and system integration, improve patient-provider communication, and streamline insurance criteria and processes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.